Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05705518 · ClinicalTrials.gov registry record · Phase 4
Artificial Tears, Tear Lipids and Tear Film Dynamics
A Phase 4 study, sponsored by University of California, Berkeley.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT05705518: Completed Phase 4 study, sponsored by University of California, Berkeley.
NCT05705518 is a Phase 4 study that has completed, run by University of California, Berkeley. The registered enrollment target is 81 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05705518, a Phase 4 study, has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
Dry eye disease (DED) is pervasive with some reports estimating over 16 million adults diagnosed in the United States. Currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. Recent studies have shown there may be therapeutic benefits with regular use of lipid-based artificial tears to improve the structure of the tear film, which may improve tear film stability and provide relief of symptoms. In this study the investigators propose to compare effects on the tear lipid film and its dynamics between 3 lipid based artificial tears and a widely available non-lipid based artificial tear.
Primary Outcome
Change in Tear Lipid Layer Thickness (3mo follow-up - post-run-in baseline)
Interventions
- DRUG Systane Complete PF
- DRUG Refresh Relieva PF
- DRUG Refresh Optive Mega-3 PF
- DRUG CVS Health Lubricant Eye Drop (PG 0.6%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 4 |
What the finished NCT05705518 record still lists
NCT05705518 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 4 interventions - of which Systane Complete PF is the first listed.
NCT05705518 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05705518 about?
NCT05705518 is a clinical study titled "Artificial Tears, Tear Lipids and Tear Film Dynamics". Dry eye disease (DED) is pervasive with some reports estimating over 16 million adults diagnosed in the United States. Currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. Recent studies have shown there may be therapeutic benefits with...
What is the current status of trial NCT05705518?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2023-01-30. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT05705518?
The interventions under investigation include: Systane Complete PF (DRUG), Refresh Relieva PF (DRUG), Refresh Optive Mega-3 PF (DRUG), CVS Health Lubricant Eye Drop (PG 0.6%) (DRUG).
Who is sponsoring clinical trial NCT05705518?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05705518's enrollment target sits among peer trials
81 940th of 2000 higher than 1,055 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI